Liposomal Amphotericin B
Treatment for Visceral Leishmaniasis
Typical Dosage: 3-5 mg/kg daily or every other day for total 15-25 mg/kg
Effectiveness
96%
Safety Score
50%
Clinical Trials
18
Participants
5.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
3-5 mg/kg daily or every other day for total 15-25 mg/kg
Time to Effect
1-2 weeks
Treatment Duration
2-10 days (typically 5-7 days)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$6,000
Monitoring:$10,000
Side Effect Mgmt:$2,000
Total Annual:$18,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$18,750
Cost per Remission
$18,750
Comparison vs Sodium Stibogluconate
Cost Difference
+$9,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Liposomal Amphotericin B Outcomes
for Visceral Leishmaniasis
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
14 completed trials for Liposomal Amphotericin B in Visceral Leishmaniasis
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
NCT03636659COMPLETEDPHASE1
140 participants
INTERVENTIONAL
Dhaka, Bangladesh +2 more
Started: May 2, 2018
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
NCT00628719COMPLETEDPHASE3
400 participants
INTERVENTIONAL
Muzaffarpur, India
Started: Feb 1, 2008
To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar
NCT00876824COMPLETEDPHASE3
500 participants
INTERVENTIONAL
Muzaffarpur, India +3 more
Started: Jul 1, 2009
Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
NCT02011958COMPLETEDPHASE3
59 participants
INTERVENTIONAL
Abdurafi, Ethiopia +1 more
Started: Jul 1, 2014
Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
NCT00371995COMPLETEDPHASE2
150 participants
INTERVENTIONAL
Muzaffarpur, India +1 more
Started: Oct 1, 2007
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
NCT01122771COMPLETEDPHASE3
602 participants
INTERVENTIONAL
Bhaluka, Bangladesh +3 more
Started: May 1, 2010
Combination Therapy in Indian Visceral Leishmaniasis
NCT00523965COMPLETEDPHASE3
624 participants
INTERVENTIONAL
Muzaffarpur, India
Started: Sep 1, 2007
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
NCT01067443COMPLETEDPHASE2
151 participants
INTERVENTIONAL
Kimalel, Kenya +2 more
Started: Mar 1, 2010
Combination Chemotherapy for the Treatment of Indian Kala-Azar
NCT00370825COMPLETEDPHASE2
200 participants
INTERVENTIONAL
Muzaffarpur, India
Started: Sep 1, 2006
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
NCT00696969COMPLETEDPHASE3
634 participants
INTERVENTIONAL
Muzaffarpur, India +1 more
Started: Jun 1, 2008
Human Bioequivalence Study of Amphotericin B Liposome for Injection
NCT06977490COMPLETEDNA
42 participants
INTERVENTIONAL
Jinan, China
Started: May 13, 2025
Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh
NCT03311607COMPLETEDPHASE4
280 participants
INTERVENTIONAL
Started: Apr 8, 2014
Human Bioequivalence Study of Liposomal Amphotericin B for Injection
NCT06983665COMPLETEDNA
58 participants
INTERVENTIONAL
Jinan, China
Started: May 25, 2025
A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis
NCT05593666COMPLETEDPHASE2
101 participants
INTERVENTIONAL
Bīhar, India +1 more
Started: Dec 27, 2022